FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235- 0104						
Estimated average burden							
hours per	0.5						

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SR One Capital Fund I Aggregator LP		Requiring (Month/D	2. Date of Event Requiring Statement (Month/Day/Year) 03/25/2021 3. Issuer Name and Ticker or Trading Symbol Design Therapeutics, Inc. [DSGN]							
I	(First)	(Middle) OL ROAD	,		4. Relationship of Repor Issuer (Check all applicable) Director	X 10% O	wner 6. Ir	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing		
SUITE 511 (Street)		_		Officer (give title below)	Other below)	. , [(0	(Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One			
WAYNE ————	PA	19087	_					Reporting F	Person	
(City)	(State)	(Zip)								
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)					irect Owne	4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
Ex		2. Date Exerc Expiration Day/Y	ate	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr.		
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	or Indirect (I) (Instr. 5)	5)	
Series A Pref	ferred Stock		(1)	(1)	Common Stock	4,439,839	(1)	D ⁽²⁾		
Series B Pref	erred Stock		(1)	(1)	Common Stock	936,637	(1)	D ⁽²⁾		

Explanation of Responses:

- 1. All outstanding shares of Preferred Stock will automatically convert into shares of Common Stock at a rate of 1 share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect, at the Reporting Person's election and automatically upon the closing of the initial public offering of Design Therapeutics, Inc. (the "Issuer"). The Preferred Stock has no expiration date.
- 2. The reported securities are held directly by SR One Capital Fund I Aggregator, LP. SR One Capital Partners I, LP is the general partner of SR One Capital Fund I Aggregator, LP, and SR One Capital Management, LLC is the general partner of SR One Capital Partners I, LP. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital Partners I, LP, SR One Capital Management, LLC and Mr. George may each be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Remarks:

SR ONE CAPITAL FUND I AGGREGATOR, L.P.,
By: SR One Capital

by. 3K One Capital

Partners I, LP, its General

Partner, By: SR One 03/25/2021
Capital Management,

LLC, its General Partner,

By: /s/ Simeon George,

Member

** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.